Correction: Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL

Correction on: Wang J, Cui R, Qi Y, Mu J, Li X, Li Q and Deng Q (2026) Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL. Front. Immunol. 17:1674235. doi: 10.3389/fimmu.2026.1674235.Adding/removing text In the abstract, two typographical errors were identified. In the last sentence of the Patients and Methods section, the original version incorrectly stated: "These 33 patients were stratified into two groups based on the duration of BTKi exposure: ≥x months versus <2 months." In the first sentence of the Results section, it incorrectly stated: "The R/R DLBCL patients receiving BTKi for ≥o months demonstrated a higher overall response rate than the patients receiving BTKi for <2 month.". The corrected abstrac has been read: "These 33 patients were stratified into two groups based on the duration of BTKi exposure: ≥2 months versus <2 months," and "The R/R DLBCL patients receiving BTKi for ≥2 months demonstrated a higher overall response rate than the patients receiving BTKi for <2 months."The original version of this article has been updated.